Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to -$10.8 million.

  • Pharmaceuticals' Net Income towards Common Stockholders fell 2802.46% to -$10.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$29.4 million, marking a year-over-year decrease of 1384.49%. This contributed to the annual value of -$38.1 million for FY2024, which is 4356.45% down from last year.
  • Per Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at -$10.8 million for Q2 2025, which was down 2802.46% from -$10.1 million recorded in Q1 2025.
  • In the past 5 years, Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$3.3 million in Q4 2023 and a low of -$48.8 million during Q4 2022
  • In the last 4 years, Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$7.8 million in 2023 and averaged -$10.9 million.
  • Within the past 5 years, the most significant YoY rise in Pharmaceuticals' Net Income towards Common Stockholders was 9323.48% (2023), while the steepest drop was 4747.3% (2023).
  • Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$48.8 million in 2022, then skyrocketed by 93.23% to -$3.3 million in 2023, then tumbled by 156.48% to -$8.5 million in 2024, then fell by 28.02% to -$10.8 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$10.8 million for Q2 2025, versus -$10.1 million for Q1 2025 and -$8.5 million for Q2 2024.